Terms: = Skin cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
35 results:
1. The role of thymic stromal lymphopoietin in cutaneous disorders.
Jafari AJ; Rivera M; Hebert AA
Arch Dermatol Res; 2024 Apr; 316(5):123. PubMed ID: 38630260
[TBL] [Abstract] [Full Text] [Related]
2. Radix Tetrastigma Hemsleyani Flavone represses cutaneous squamous cell carcinoma via Janus kinase/signal transducer and activator of transcription 3 pathway inactivation.
Peng J; Luo X; Wang T; Yue C; Duan M; Wu C
Cytokine; 2024 Mar; 175():156480. PubMed ID: 38232644
[TBL] [Abstract] [Full Text] [Related]
3. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract] [Full Text] [Related]
4. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P; Iannotti N; Cho DC; Kirkwood JM; Villaruz LC; Gibney GT; Hodi FS; Mettu NB; Jones M; Bowman J; Smith M; Lakshminarayanan M; O'Day S
Cancer Res Commun; 2023 Dec; 3(12):2572-2584. PubMed ID: 38115208
[TBL] [Abstract] [Full Text] [Related]
5. Successful treatment of jak1-associated inflammatory disease.
Fayand A; Hentgen V; Posseme C; Lacout C; Picard C; Moguelet P; Cescato M; Sbeih N; Moreau TRJ; Zhu YYJ; Charuel JL; Corneau A; Deibener-Kaminsky J; Dupuy S; Fusaro M; Hoareau B; Hovnanian A; Langlois V; Le Corre L; Maciel TT; Miskinyte S; Miyara M; Moulinet T; Perret M; Schuhmacher MH; Rignault-Bricard R; Viel S; Vinit A; Soria A; Duffy D; Launay JM; Callebert J; Herbeuval JP; Rodero MP; Georgin-Lavialle S
J Allergy Clin Immunol; 2023 Oct; 152(4):972-983. PubMed ID: 37343845
[TBL] [Abstract] [Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Landis MN; Smith SR; Berstein G; Fetterly G; Ghosh P; Feng G; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Beebe JS; Tarabar S
Br J Dermatol; 2023 Jul; 189(1):33-41. PubMed ID: 36972293
[TBL] [Abstract] [Full Text] [Related]
8. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract] [Full Text] [Related]
9. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract] [Full Text] [Related]
10. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma.
Gluud M; Pallesen EMH; Buus TB; Gjerdrum LMR; Lindahl LM; Kamstrup MR; Bzorek M; Danielsen M; Bech R; Monteiro MN; Blümel E; Willerslev-Olsen A; Lykkebo-Valløe A; Vadivel CK; Krejsgaard T; Bonefeld CM; Geisler C; Becker JC; Koralov SB; Iversen L; Litman T; Woetmann A; Ødum N
Blood; 2023 Jan; 141(2):180-193. PubMed ID: 36122387
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Landis MN; Arya M; Smith S; Draelos Z; Usdan L; Tarabar S; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Sikirica V; Xenakis J; Beebe JS
Br J Dermatol; 2022 Dec; 187(6):878-887. PubMed ID: 35986699
[TBL] [Abstract] [Full Text] [Related]
12. Management of Myelofibrosis during treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.
Breccia M; Palandri F; Guglielmelli P; Palumbo GA; Malato A; Mendicino F; Ricco A; Sant'Antonio E; Tiribelli M; Iurlo A
Curr Oncol; 2022 Jul; 29(7):4970-4980. PubMed ID: 35877255
[TBL] [Abstract] [Full Text] [Related]
13. Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.
Yi G; Huang Z; Huang Z; Wang Y; Deng W; Zheng S; Li T
Front Immunol; 2022; 13():914265. PubMed ID: 35874753
[TBL] [Abstract] [Full Text] [Related]
14. Kinase Inhibition as treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract] [Full Text] [Related]
15. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
[TBL] [Abstract] [Full Text] [Related]
16. Integrated Safety Analysis of Abrocitinib for the treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract] [Full Text] [Related]
17. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract] [Full Text] [Related]
18. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract] [Full Text] [Related]
19. Novel TMEM173 Mutation and the Role of Disease Modifying Alleles.
Keskitalo S; Haapaniemi E; Einarsdottir E; Rajamäki K; Heikkilä H; Ilander M; Pöyhönen M; Morgunova E; Hokynar K; Lagström S; Kivirikko S; Mustjoki S; Eklund K; Saarela J; Kere J; Seppänen MRJ; Ranki A; Hannula-Jouppi K; Varjosalo M
Front Immunol; 2019; 10():2770. PubMed ID: 31866997
[TBL] [Abstract] [Full Text] [Related]
20. Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.
Chan MP; Plouffe KR; Liu CJ; Palanisamy N; Carskadon S; Zhao L; Nazarian RM; Durham AB; Johnson TM; Andea AA; Patel RM; Lowe L; Fullen DR; Brown NA; Tomlins SA; Udager AM; Harms PW
Mod Pathol; 2020 Jun; 33(6):1092-1103. PubMed ID: 31857679
[TBL] [Abstract] [Full Text] [Related]
[Next]
